Morgan Sindall has won a contract to develop a £60m Array Multiplex science research building at Granta Park in Cambridge, UK.
The research building is being developed for BioMed Realty Trust which owns, manages and operates Granta Park.
BioMed Realty Cambridge Market Lead Douglass Cuff said: "We are looking forward to working with Morgan Sindall to complete this new state-of-the-art 155,000ft² facility for Illumina at Granta Park.
"This expansion of our Granta Park development reinforces Cambridge’s standing as one of the premier global core innovation districts for the life science industry."
The new development has been planned as a three-storied concrete frame building that will serve as the new European headquarters for biotechnology company Illumina.
It will feature scientific research space, including a data centre which will be capable of handling Illumina’s data requirement.
The centre is aimed at offering the biomedical firm with a collaborative environment and access to the highly skilled workforce in the dynamic research cluster anchored by Cambridge University.
The building has been planned to include sustainable features with brise soleil vertical solar shading panels that can help it to maintain its temperature and prevent overheating.
Morgan Sindall will also be developing a three-storey winter garden as a part of the new project.
Morgan Sindall area director Bob Ensch said: "The building will utilise next-generation ‘smart’ technology and help to ensure the building operates at optimum capacity throughout its lifetime.
"Our project team will draw on knowledge gleaned from its extensive experience delivering world-class research facilities and will be bringing that insight to bear on this development."
UK Minister for Life Sciences George Freeman said: "This is a strong endorsement of the UK’s Life Science Industrial Strategy and leadership in driving forward better treatments for people with cancers and rare diseases."
Image: Array Multiplex science research building. Photo: courtesy of Morgan Sindall plc.